摘要
非甾体抗炎药(nonsteroidal anti-inflammatory drugs,NSAIDs)广泛用于多种关节炎的治疗,然而临床使用中发现,传统的非甾体抗炎药缺乏靶点选择性,胃肠道(gastrointestinal,GI)不良反应严重。选择性COX-2抑制剂如罗非昔布等尽管可能降低GI不良反应,但其心血管毒性风险增加。最新研究表明,选择性COX-2抑制剂并没有显著改善传统NSAIDs的GI损伤。近几年,NSAIDs引发的小肠黏膜损伤引起了广泛的关注,且至今还无有效方法消除这一损伤。因此,现有NSAIDs的安全性问题仍然突出。为提高现有NSAIDs的安全性,研究者开始着眼于研发新型安全性更高的非甾体抗炎药。本文主要介绍目前最新的安全性高的NSAIDs,并对其研究进行了展望。
Nonsteroidal anti-inflammatory drugs( NSAIDs) are widely used in the treatment of many kinds of arthritis. However,the traditional NSAIDs have significant gastrointestinal( GI) side effects owing to the lack of targets selectivity in the clinical use. The latter COX-2 inhibitors rofecoxib may reduce the GI side effects,but increased the risk of serious cardiovascular toxicity. Furthermore,some latest researches have shown that the selective COX-2 inhibitors could not significantly reduce the GI damage compared to traditional NSAIDs. In recent years,NSAIDs induced small bowel injury has become a topic with no effective method to deal,which deserves our attention. Thus,the safety issues of the existing NSAIDs are still outstanding. Researchers are focusing on the development of newer and safer NSAIDs. This review mainly introduced the latest research directions,and makes a prospect of the safer NSAIDs in the future.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第11期1258-1265,共8页
Chinese Journal of New Drugs